Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

• Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
• ASCENT trial: Survival advantage with sacituzumab govitecan versus physician’s choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
• Treatment-associated side effects with sacituzumab govitecan (5:32)
• Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
• Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
• Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
• Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)

CME information and select publications

Featuring an interview with Dr Tiffany A Traina, including the following topics:

• Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
• Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
• Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
• Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
• Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
• Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
• Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
• Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
• Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
• Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)

CME information and select publications

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics:

• Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00)
• Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27)
• Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56)
• Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00)
• Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25)
• Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33)
• Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05)
• Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15)
• Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25)
• New Directions in the Management of BTCs — Dr Javle (2:01:09)

CME information and select publications